

■ **BEHAVIORAL PHARMACOLOGY AND GENETICS: TRANSLATING AND TARGETING INDIVIDUAL DIFFERENCES (R03): RFA-DA-09-016**

Components of Participating Organizations
National Institute on Drug Abuse

Letters of Intent Receipt Date(s): December 29, 2008
Application Due Date(s): January 27, 2009
Earliest Anticipated Start Date(s): September 2009

Individual differences in response to drugs of abuse may confer vulnerability or resistance to drug abuse or the development of addiction. Several lines of evidence indicate that genetic variation contributes to drug abuse and addiction as well as to the propensity to use specific classes of drugs, such as psychostimulants, opiates, marijuana and nicotine. Recently developed genetic methodologies make it possible to better understand drug abuse phenotypes in terms of underlying genetic factors. This FOA seeks applications that use controlled, human laboratory-based experimental techniques for the measurement of behavior, combined with genetic analyses, to study drug abuse phenotypes and/or endophenotypes, and their relationship to (a) individual differences in response to drugs of abuse; (b) individual differences in the consequences of repeated abuse; or (c) pharmacogenetic differences in response to putative or currently used pharmacotherapeutic agents for treating addiction. Research in these areas may identify genetic variations that will help define the biochemical mechanisms underlying drug effects and the associated biological and/or behavioral processes responsible for individual differences, and may suggest genetically targeted pharmacotherapeutic approaches for treating addiction.

This FOA will utilize the R03 grant mechanism to support projects including pilot and feasibility studies; small, self-contained research projects; and to foster the establishment of new research collaborations between geneticists and drug abuse researchers. As the R03 is intended to support small research projects that can be carried out in a short period of time with limited resources, it is intended that, with the use of this mechanism, investigators and collaborative research groups will be able to conduct initial pilot and feasibility studies to better position them for a subsequent R01 application. The total amount of funding that NIDA expects to award through this announcement is \$2,000,000 for an anticipated 8–10 awards. Budgets for direct costs of up to \$150,000 per year and a project duration of up to two years may be requested for a maximum of \$300,000 direct costs over a two-year project period. Items 2–5 of the PHS398 Research Plan component of the R03 application may not exceed 10 pages, including tables, graphs, figures, diagrams, and charts. See http://grants.nih.gov/grants/funding/funding_program.htm

Eligible institutions and organizations include: public and state controlled institutions of higher education; private institutions of higher education; Hispanic-serving institutions; Historically Black Colleges and Universities; Tribally Controlled Colleges and Universities; Alaska Native- and Native Hawaiian- serving institutions; nonprofit organizations with 501(c)(3) IRS status (other than institutions of higher education); nonprofit organizations without 501(c)(3) IRS status (other than institutions of higher education); small businesses; for-profit organizations (other than small businesses); state

governments; Indian/Native American tribal governments (federally recognized); Indian/Native American tribally designated organizations; county governments; city or township governments; special district governments; Independent School Districts; public housing authorities/Indian housing authorities; U.S. territories or possessions; Indian/Native American tribal governments (other than federally recognized); regional organizations; non-domestic (non-U.S.) entities (foreign organizations); eligible agencies of the federal government; and faith-based or community-based organizations. Individuals with the skills, knowledge, and resources necessary to carry out the proposed research are invited to work with their institution/organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. More than one PD/PI (i.e., multiple PDs/Pis) may be designated on the application. Applicants may submit more than one application, provided each application is scientifically distinct. Resubmission applications are not permitted in response to this FOA. The R03 is not renewable. This FOA uses non-standard due dates.

Complete details available online at <http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-09-016.html>

■ **FINE MAPPING AND FUNCTION OF GENES FOR TYPE 1 DIABETES (DP3): RFA-DK-08-006**

Components of Participating Organizations

This FOA is developed as part of the Strategic Plan for Type 1 Diabetes Research (<http://www.T1Diabetes.nih.gov/plan>), and is supported by the Special Statutory Program for Type 1 Diabetes Research. This FOA is being administered by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) on behalf of the NIH.

Opening Date: February 27, 2009 (Earliest date an application may be submitted to Grants.gov)

Letters of Intent Receipt Date(s): February 27, 2009

Application Due Date(s): March 30, 2009

Earliest Anticipated Start Date(s): September, 2009

This FOA issued by the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, solicits Research Project Grant (DP3) applications from institutions/organizations for research on projects to carry out fine mapping studies as well as to investigate the function of the genes involved in type 1 diabetes. To date, genome-wide association studies (GWAS) of type 1 diabetes have yielded promising results. However, follow-up studies are needed to eliminate false positives, extend the findings to diverse populations (diverse in terms of ethnicity or environmental exposures) and narrow the association interval. The purpose of this funding opportunity is to provide support for replication and fine-mapping studies of genetic regions putatively associated with type 1 diabetes. In addition, studies of the function of the genes identified and the mechanisms by which they may alter risk are needed. This initiative will also solicit proposals on the application of new technologies to genetics of type 1 diabetes and the study of the role of these genes in the etiopathogenesis of type 1 DM. The identification of these genes and function will help define etiological pathways and leads for new therapeutic targets.

This FOA will utilize the DP3 grant mechanism. The total funding for this five year program this year is \$20 million for the five year period. It is anticipated that 4–10 awards will be made. The maximum direct costs are \$5 million that can be spent on a project period of up to 5 years. NIDDK expects that the requested direct costs will range from \$1.5–5 million based on the scope of the research, plus applicable Facilities and Administrative costs to be determined at the time of the award.

Eligible institutions and organizations include: public and state controlled institutions of higher education; private institutions of higher education; Hispanic-serving institutions; Historically Black Colleges and Universities; Tribally Controlled Colleges and Universities; Alaska Native- and Native Hawaiian-serving institutions; nonprofit organizations with 501(c)(3) IRS status (other than institutions of higher education); nonprofit organizations without 501(c)(3) IRS status (other than institutions of higher education); small businesses; for-profit organizations (other than small businesses); non-domestic (non-U.S.) entities (foreign organizations); and eligible agencies of the federal government. Individuals with the skills, knowledge, and resources necessary to carry out the proposed research are invited to work with their institution/ organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. More than one PD/PI (i.e., multiple PDs/Pis) may be designated on the application. Applicants may submit more than one application, provided each application is scientifically distinct. Resubmission applications are not permitted in response to this FOA. Renewal applications are not permitted in response to this FOA. This FOA uses non-standard due dates.

Complete details available online at <http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-08-006.html>

■ NHLBI PEDIATRIC CARDIAC GENOMICS CONSORTIUM (U01): RFA-HL-09-003

Components of Participating Organizations

*National Heart, Lung, and Blood Institute
Institute of Circulatory and Respiratory Health*

Letters of Intent Receipt Date: January 6, 2009
Application Receipt Date: February 6, 2009
Earliest Anticipated Start Date: September 1, 2009
One or more pre-submission web conferences will be held. Details will be posted on the FOA FAQ site, <http://www.nhlbi.nih.gov/funding/inits/faq-ptc.htm>

The National Heart, Lung, and Blood Institute (NHLBI) and the Canadian Institutes of Health Research (CIHR) invite applications to participate in a new NHLBI Pediatric Cardiac Genomics Consortium, a cooperative investigative group that will conduct clinical and translational research on the genetic causes of congenital heart disease and genetic contributions to outcome in individuals with congenital heart disease. The purpose of this initiative is to support collaborative genetic and genomic research leading to a comprehensive understanding of the causes and outcomes of congenital heart disease in the human population. The Consortium will consist of up to 6 Research Centers, Cores, and a Steering Committee. Research Center applicants will propose detailed investigation of the genetics and genomics of one or more human cardiac malformations, with the goal of identifying genetic influences on outcome, as well as causative genes. Individual Research Centers will collaborate in recruitment of individuals with congenital heart disease and their families for all Research Center projects. This Consortium is

part of a new NHLBI translational program in pediatric cardiovascular disease, which includes the companion NHLBI Cardiac Development Consortium (<http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-09-002.html>), and Administrative Coordinating Center for both Consortia (<http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-09-011.html>). These consortia will interact with each other and with the NHLBI Pediatric Heart Network (www.PediatricHeartNetwork.com) to encourage translation of results from basic science to clinical research, and to provide clinical input on pressing needs for basic research.

This FOA will utilize the Research Project Cooperative Agreement (U01) mechanism of support. The NHLBI intends to commit approximately \$1,440,000 total costs for FY2009. The total amount to be awarded for the Pediatric Cardiac Genomics Consortium will be a maximum of \$25,440,000 total costs for the six-year project period. It is anticipated that up to 6 research centers will be awarded. The total project period for an application submitted in response to this FOA is 6 years, the first year of which will be a planning year. Maximum allowable direct costs for the Research Centers per year are \$160,000 in Year 1, and \$535,000 per year in years 2–6.

Eligible institutions and organizations include public and state controlled institutions of higher education; private institutions of higher education; Hispanic-serving institutions; Historically Black Colleges and Universities; Tribally Controlled Colleges and Universities; Alaska Native- and Native Hawaiian- serving institutions; nonprofit organizations with 501(c)(3) IRS status (other than institutions of higher education); nonprofit organizations without 501(c)(3) IRS status (other than institutions of higher education); small businesses; for-profit organizations (other than small businesses); state governments; non-domestic (non-U.S.) entities in North America; and eligible agencies of the federal government. Individuals with the skills, knowledge, and resources necessary to carry out the proposed research are invited to work with their institution/organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. More than one PD/PI (i.e., multiple PDs/Pis), may be designated on the application. Applicants may submit more than one application, provided they are scientifically distinct. Resubmission applications are not permitted in response to this FOA. Renewal applications are not permitted in response to this FOA. This FOA uses non-standard due dates.

Complete details available online at <http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-09-003.html>

■ NEUROIMAGING IN OBESITY RESEARCH (R01): RFA-DK-08-009

Components of Participating Organizations

National Institute of Diabetes and Digestive and Kidney Diseases

National Institute on Drug Abuse

National Institute of Biomedical Imaging and Bioengineering

Letters of Intent Receipt Date(s): February 18, 2009
Opening Date: February 18, 2009 (Earliest date an application may be submitted to Grants.gov)
Application Due Date(s): March 18, 2009
Earliest Anticipated Start Date(s): December 1, 2009

This FOA issued by the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute on Drug

Abuse, and the National Institute of Biomedical Imaging and Bioengineering, of the National Institutes of Health, solicits Research Project Grant (R01) applications from institutions/organizations that propose to use neuroimaging approaches in obesity research in human subjects and animal models. Many areas of the brain interact or communicate with other organs to control eating behavior, physical activity and energy metabolism, and functional neuroimaging holds enormous promise for expanding our understanding of how food intake and energy expenditure are mismatched in a setting of abundantly available nutrients, leading to excessive fat storage.

This FOA will utilize the R01 grant mechanism. The total amount of funding that the ICs expect to award through this announcement is up to \$4.5 Million, to fund approximately 9–15 awards. The duration and requested direct costs will vary depending on the scope of the proposed research, but cannot exceed 5 years and \$500,000 per year. The R01 application Research Plan component of the PHS398 (Items 2–5) may not exceed 25 pages, including tables, graphs, figures, diagrams, and charts (see http://grants.nih.gov/grants/funding/funding_program.htm).

Eligible institutions and organizations include public and state controlled institutions of higher education; private institutions of higher education; Hispanic-serving institutions; Historically Black Colleges and Universities; Tribally Controlled Colleges and Universities; Alaska Native- and Native Hawaiian- serving institutions; nonprofit organizations with 501(c)(3) IRS status (other than institutions of higher education); nonprofit organizations without 501(c)(3) IRS status (other than institutions of higher education); small businesses; for-profit organizations (other than small businesses); state governments; Indian/Native American tribal governments (federally recognized); Indian/Native American tribally designated organizations; U.S. territories or possessions; regional organizations; non-domestic (non-U.S.) entities (foreign organizations); eligible agencies of the federal government; and faith-based or community-based organizations. Individuals with the skills, knowledge, and resources necessary to carry out the proposed research are invited to work with their institution/organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. More than one PD/PI (i.e., multiple PDs/Pis) may be designated on the application. Applicants may submit more than one application, provided each application is scientifically distinct. Resubmission applications are not permitted in response to this FOA. Renewal applications are not permitted in response to this FOA. This FOA uses non-standard due dates.

Complete details available online at: <http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-08-009.html>

■ 2009 NIH DIRECTOR'S PIONEER AWARD PROGRAM (DP1): RFA-RM-09-001

Components of Participating Organizations

This FOA is developed as an NIH Roadmap Initiative, <http://nihroadmap.nih.gov>. All NIH Institutes and Centers are participating. This FOA is being administered by the National Institute of General Medical Sciences (NIGMS) on behalf of NIH.

Letters of Intent Receipt Date(s): Not applicable
Opening Date: April 15, 2009 (Earliest date an application may be submitted to Grants.gov)

Application Due Date(s): May 15, 2009
Reference Letter Submission/Receipt Dates: April 15, 2009–5:00 pm (EDT) May 15, 2009
Earliest Anticipated Start Date(s): September 30, 2009
Expiration Date: May 16, 2009

The NIH Director's Pioneer Award Program complements NIH's traditional, investigator-initiated grant programs by supporting individual scientists of exceptional creativity who propose pioneering and possibly transformative approaches to addressing major biomedical or behavioral challenges. To be considered pioneering, the proposed research must reflect ideas substantially different from those already being pursued in the investigator's laboratory or elsewhere. The NIH Director's Pioneer Award Program is a High-Risk Research initiative of the NIH Roadmap for Medical Research. The 2009 Pioneer Award competition will proceed in two phases. The first phase is a pre-application phase in response to PAR-09-012. Pre-applications will be evaluated by a group of external reviewers, and those investigators whose submissions are judged to be the most outstanding will be notified of the opportunity to submit full applications under this FOA. The 2009 Pioneer awardees will be selected from this group of applicants.

This FOA will utilize the DP1 grant mechanism. Pre-applications for 2009 Pioneer Awards were solicited under PAR-09-012. Applicants must read both FOAs. Total funding available is approximately \$5 million for the five-year period. It is anticipated that at least 5–10 awards will be made in 2009. Awards will be for up to \$500,000 in direct costs each year for five years.

Eligible institutions and organizations include: public and state controlled institutions of higher education; private institutions of higher education; Hispanic-serving institutions; Historically Black Colleges and Universities; Tribally Controlled Colleges and Universities; Alaska Native- and Native Hawaiian-serving institutions; nonprofit organizations with 501(c)(3) IRS status (other than institutions of higher education); nonprofit organizations without 501(c)(3) IRS status (other than institutions of higher education); small businesses; for-profit organizations (other than small businesses); state governments; Indian/Native American tribal governments (federally recognized); Indian/Native American tribally designated organizations; U.S. territories or possessions; Indian/Native American tribal governments (other than federally recognized); regional organizations; eligible agencies of the federal government; and faith-based or community-based organizations. Foreign organizations are not eligible to apply. Only investigators who submitted a pre-application (X02), in response to PAR-09-012 are eligible to submit full applications under this FOA. Recipients of the Pioneer Award (DP1) are required to commit the major portion (at least 51%) of their research effort to activities supported by the Pioneer Award. Applicants who were not selected for an award in prior years may submit pre-applications this year. There are no citizenship or residency requirements. Only one PD/PI (i.e., no multiple PDs/Pis) may be designated on the application. Applicants may submit only one application as a PD/PI in response to this FOA. There is no limit to the number of applications that an institution may submit. Resubmission applications are not allowed. All applications must be submitted as "new" regardless of any previous submissions to the Program. Renewal applications are not permitted in response to this FOA. This FOA uses non-standard due dates.

Complete details available online at <http://grants.nih.gov/grants/guide/rfa-files/RFA-RM-09-001.html>

■ 2009 NIH DIRECTOR'S NEW INNOVATOR AWARD PROGRAM (DP2): RFA-RM-09-003

This Funding Opportunity Announcement (FOA) is a reissue of RFA-RM-08-014.

Components of Participating Organizations

This FOA is developed as an NIH Roadmap initiative (http://grants.nih.gov/grants/new_investigators/innovator_award/); all NIH Institutes and Centers are participating. This FOA is being administered by the National Institute of General Medical Sciences (NIGMS) on behalf of the NIH.

Letters of Intent Receipt Date(s): Not applicable
 Opening Date: April 29, 2009 (Earliest date an application may be submitted to Grants.gov)
 Application Due Date(s): May 27, 2009
 Earliest Anticipated Start Date(s): September 30, 2009
 Expiration Date: May 28, 2009

The NIH Director's New Innovator (DP2) Award program was created in 2007 to support a small number of new investigators of exceptional creativity who propose bold and highly innovative new research approaches that have the potential to produce a major impact on broad, important problems in biomedical and behavioral research. The New Innovator Awards complement ongoing efforts by NIH and its Institutes and Centers to fund new investigators through R01 grants, which continue to be the major sources of NIH support for new investigators. The competition for the New Innovator Award in fiscal year 2009 will proceed in two phases. The first phase is a pre-application phase in response to PAR-09-013. Pre-applications will be evaluated by a group of external reviewers, and those investigators whose submissions are judged to be the most outstanding will be notified of the opportunity to submit full applications under this FOA. The 2009 New Innovator Awardees will be selected from this group of applicants.

This FOA will utilize the DP2 grant mechanism. Pre-applications for 2009 New Innovator Awards were solicited under PAR-09-013. Applicants should read both FOAs. Total funding available is approximately \$55.7 million for the five-year period. It is anticipated that up to 24 awards will be made in 2009. Awards will be for up to \$300,000 in direct costs each year for five years. Standard F&A costs will be determined at the time of award.

Eligible institutions and organizations include public and state controlled institutions of higher education; private institutions of higher education; Hispanic-serving institutions; Historically Black Colleges and Universities; Tribally Controlled Colleges and Universities; Alaska Native- and Native Hawaiian- serving institutions; nonprofit organizations with 501(c)(3) IRS status (other than institutions of higher education); nonprofit organizations without 501(c)(3) IRS status (other than institutions of higher education); small businesses; for-profit organizations (other than small businesses); state governments; Indian/Native American tribal governments (federally recognized); Indian/Native American tribally designated organizations; U.S. territories or possessions; Indian/Native American tribal governments (other than federally recognized); regional organizations; eligible agencies of the federal government; and faith-based or community-based organizations. Foreign organizations are not eligible to apply. Only investigators who submitted a pre-application in response to PAR-09-013 are eligible to submit full applications under this FOA. Recipi-

ents of the New Innovator Award (DP2) are required to commit 25% of their research effort to activities supported by the New Innovator Award. Applicants who were not selected for an award in prior years may submit pre-applications this year. There are no citizenship or residency requirements. Only one PD/PI may be designated on the application. Applicants may submit only one application as a PD/PI in response to this FOA. There is no limit to the number of applications that institutions may submit. Resubmission applications are not allowed. All applications must be submitted as "new" regardless of any previous submissions to the Program. Renewal applications are not permitted in response to this FOA. This FOA uses non-standard due dates.

Complete details available online at <http://grants.nih.gov/grants/guide/rfa-files/RFA-RM-09-003.html>

■ INTESTINAL STEM CELL CONSORTIUM (U01) RFA-DK-08-010

Components of Participating Organizations

National Institute of Diabetes and Digestive and Kidney Diseases

National Institute of Allergy and Infectious Diseases

Release Date: October 29, 2008
 Application Receipt Date: March 18, 2009
 Earliest Anticipated Start Date: September, 2009

This FOA invites new applications to participate in the Intestinal Stem Cell Consortium (ISCC). The goals of this initiative are 1) to establish a network of synergistic research teams and a Coordinating Center focused on research on stem cells of the small intestine in order to 2) isolate, culture, characterize, functionally validate, and compare stem cell populations from the small intestine epithelium in vivo and in vitro, and 3) share data, bio-materials, models, reagents, resources and methods between projects in the ISCC and 4) make these publicly available through a web site to be developed by the Coordinating Center. The objective of support for this consortium is to accelerate research on stem cells of the intestinal epithelium in order to facilitate understanding of the biology and function of the intestine and aid development of therapies for intestinal diseases and conditions where damage and replacement of this epithelium are important components.

This FOA will utilize the U01 cooperative agreement grant mechanism. The total amount of funding that is expected to be awarded through this announcement is \$3.0 Million total costs for the first year to support 5–7 research projects and one Coordinating Center. The total project period for an application submitted in response to this funding opportunity may not exceed five years. Direct costs are limited to \$250,000 per year for a maximum five-year period for research projects and \$350,000 per year for a maximum five-year period for the Coordinating Center. Depending on availability of funds, an additional \$500,000 in discretionary funds will be made available in years 2–5 for total costs of pilot projects to be administered through the Coordinating Center.

Eligible institutions and organizations include: public and state controlled institutions of higher education; private institutions of higher education; Hispanic-serving institutions; Historically Black Colleges and Universities; Tribally Controlled Colleges and Universities; Alaska Native- and Native Hawaiian- serving institutions; nonprofit organizations with 501(c)(3) IRS status (other than institutions of higher education); nonprofit organizations without 501(c)(3) IRS status

(other than institutions of higher education); small businesses; for-profit organizations (other than small businesses); state governments; Indian/Native American tribal governments (federally recognized); Indian/Native American tribally designated organizations; county governments; city or township governments; special district governments; Independent School Districts; public housing authorities/Indian housing authorities; U. S. territories or possessions; Indian/Native American tribal governments (other than federally recognized); regional organizations; eligible agencies of the federal government; and faith-based or community-based organizations. Individuals with the skills, knowledge, and resources necessary to carry out the proposed research are invited to work with their institution/organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. More than one PD/PI (i.e., multiple PDs/PIs), may be designated on the application. Applicants may submit more than one application, provided they are scientifically distinct. Resubmission applications are not permitted in response to this FOA. Renewal applications are not permitted in response to this FOA. This FOA uses non-standard due dates.

Complete details available online at <http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-08-010.html>

■ MICROBIOME OF THE LUNG AND RESPIRATORY TRACT IN HIV-INFECTED INDIVIDUALS AND HIV-UNINFECTED CONTROLS (U01): RFA-HL-09-006

Components of Participating Organizations *National Heart, Lung, and Blood Institute*

Letters of Intent Receipt Date: February 25, 2009
Application Receipt Date: March 25, 2009
Earliest Anticipated Start Date: September 30, 2009
Expiration Date: March 26, 2009

The National Heart, Lung, and Blood Institute (NHLBI) solicits grant applications under this Funding Opportunity Announcement (FOA) to characterize the microbiome of the lung (the airways and airspaces below the glottis and the lung parenchyma) alone or in combination with the nasal and/or oropharyngeal cavities in HIV-infected individuals and matched HIV-uninfected controls, including normal healthy controls, using molecular techniques to identify bacteria and if possible other organisms, e.g., viruses, cell-wall deficient organisms, protozoa, and fungi. Investigators should use high-throughput technology platforms to create a data set of sufficient quality and depth to allow analysis of how changes of microbiota relate to HIV lung disease progression/complications. These data will be used to examine the impact of changes in the respiratory microbiome on the pathogenesis and progression of HIV disease, on HIV-related respiratory complications, and the effects of anti-HIV therapies.

The National Heart, Lung, and Blood Institute (NHLBI) invites applications for four Clinical/Sequencing research sites and one supporting Data Coordinating Center (DCC). Each application for a clinical/sequencing research site should propose approaches to characterize the lung microbiome and applicants are encouraged to include at least one hypothesis-driven mechanistic aim. Applicants must agree to collaborate with the other Clinical/Sequencing sites, the DCC, and projects funded under the Roadmap HMP program on overlapping areas of interest. Inclusion of the nasal and or pharyngeal cavities is

optional. The Lung HIV Microbiome Program is designed to promote cooperation and coordination, facilitate scientific exchange, and leverage resources.

This FOA will utilize the Cooperative Agreement U01 grant mechanism and the multiple PI mechanism. Contingent upon the availability of funds and the receipt of a sufficient number of meritorious applications, the total amount to be awarded is \$20 million over five years. The anticipated number of awards is five including a DCC. Direct costs up to \$525,000 per year for project duration of up to five years may be requested by the Clinical/Sequencing Centers. From this amount \$25,000/year in direct costs must be set aside in all years for collaborative pilot studies. These pilot studies will require further development by the Steering Committee and will require the approval of the DSMB and the NHLBI Program Office before being initiated. Direct costs of up to \$525,000 per year for five years may be requested by the DCC. The DCC must plan for a five-year project period.

Eligible institutions and organizations include: public and state controlled institutions of higher education; private institutions of higher education; Hispanic-serving institutions; Historically Black Colleges and Universities; Tribally Controlled Colleges and Universities; Alaska Native- and Native Hawaiian- serving institutions; nonprofit organizations with 501(c)(3) IRS status (other than institutions of higher education); nonprofit organizations without 501(c)(3) IRS status (other than institutions of higher education); small businesses; for-profit organizations (other than small businesses); state governments; Indian/Native American tribal governments (federally recognized); Indian/Native American tribally designated organizations; county governments; city or township governments; special district governments; Independent School Districts; public housing authorities/Indian housing authorities; U.S. territories or possessions; Indian/Native American tribal governments (other than federally recognized); regional organizations; eligible agencies of the federal government; and faith-based or community-based organizations. Individuals with the skills, knowledge, and resources necessary to carry out the proposed research are invited to work with their institution/organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. More than one PD/PI (i.e., multiple PDs/PIs) should be designated on the application. Applicants may submit more than one application, provided they are scientifically distinct. Resubmission applications are not permitted in response to this FOA. Renewal applications are not permitted in response to this FOA. This FOA uses non-standard due dates.

Complete details available online at <http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-09-006.html>

■ CARDIAC TRANSLATIONAL RESEARCH IMPLEMENTATION PROGRAM (C-TRIP) (P20): RFA- HL-10-001

Components of Participating Organizations *National Heart, Lung, and Blood Institute*

Letters of Intent Receipt Date: April 28, 2009
Application Receipt Date: May 28, 2009
Earliest Anticipated Start Date: April 2010
Expiration Date: May 29, 2009

The National Heart, Lung, and Blood Institute (NHLBI) solicits Stage 1 exploratory planning (P20) applications to the Cardiac

Translational Research Implementation Program (C-TRIP). The overall objective of the entire two-staged C-TRIP is to accelerate translation of promising new therapeutic interventions derived from fundamental research discoveries for the treatment and prevention of heart failure or arrhythmias through the planning and execution of well-designed clinical trials to demonstrate safety and efficacy. Stage 1 exploratory planning (P20) applications will support the planning and development of Stage 2 specialized center (P50) applications that support the conduct of the safety and efficacy trials recommended for support following a second phase of peer review. Subsequent Stage 2 (P50) applications for the conduct of the clinical trials planned and developed during Stage 1 will be solicited at a later time. The to-be-released solicitation for Stage 2 specialized center (P50) applications will be limited to successful Stage 1 applicants. Stage 2 (P50) applications will be anticipated 18 months following the initial award of Stage 1 applications. Support during Stage 2 of C-TRIP is expected to provide up to \$1,515,000 direct costs per year for up to five years. Only two-year, Stage 1 (P20) applications are being solicited at this time.

The total project period for the Stage 1 exploratory planning (P20) applications submitted in response to the present C-TRIP announcement is two years. During this period, applicants may request no more than \$500,000 per year in direct costs for a maximum of \$1,000,000 direct costs. This FOA for Stage 1 C-TRIP applications will utilize the Exploratory Grants Mechanism (P20). Although only Stage 1 C-TRIP applications are being solicited at this time, NHLBI expects to commit \$9,000,000 per year to support the award of up to 12 two-year-long Stage 1 (P20) and four subsequent Stage 2 (P50) C-TRIP awards.

Eligible institutions and organizations include: public and state controlled institutions of higher education; private institutions of higher education; Hispanic-serving institutions; Historically Black Colleges and Universities; Tribally Controlled Colleges and Universities; Alaska Native- and Native Hawaiian- serving institutions; nonprofit organizations with 501(c)(3) IRS status (other than institutions of higher education); nonprofit organizations without 501(c)(3) IRS status (other than institutions of higher education); small businesses; for-profit organizations (other than small businesses); state governments; Indian/Native American tribal governments (federally recognized); Indian/Native American tribally designated organizations; county governments; city or township governments; special district governments; Independent School Districts; public housing authorities/Indian housing authorities; U.S. territories or possessions; Indian/Native American tribal governments (other than federally recognized); regional organizations; non-domestic (non-U.S.) entities (foreign organizations); eligible agencies of the federal government; and faith-based or community-based organizations. Individuals with the skills, knowledge, and resources necessary to carry out the proposed research are invited to work with their institution/organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. More than one PD/PI (i.e., multiple PDs/Pis) may be designated on the application. An individual can serve as a PD/PI on only one Stage 1 C-TRIP application. There are no limits on the number of Stage 1 C-TRIP applications that can be submitted by one organization. Resubmission applications are not permitted in response to this FOA. Renewal applications are not permitted in response to this FOA.

Complete details available online at <http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-10-001.html>

■ ERYTHROPOIESIS STIMULATING AGENTS AND TUMOR PROGRESSION (R01): PA-09-023

Note R21 RFA: *Erythropoiesis Stimulating Agents and Tumor Progression (R21): (PA-09-024)*

Details online at <http://grants.nih.gov/grants/guide/pa-files/PA-09-024.html>

Components of Participating Organizations National Cancer Institute

Opening Date: January 5, 2009 (Earliest date an application may be submitted to Grants.gov)

Letters of Intent Receipt Date(s): Not Applicable

Application Due Dates: Standard dates apply, please see <http://grants1.nih.gov/grants/funding/submissionschedule.htm>

AIDS Application Due Dates: Standard dates apply, please see <http://grants1.nih.gov/grants/funding/submissionschedule.htm#AIDS>.

Earliest Anticipated Start Dates: Standard dates apply, please see <http://grants1.nih.gov/grants/funding/submissionschedule.htm#reviewandaward>.

Expiration Date: January 8, 2012

This funding opportunity announcement (FOA), issued by the National Cancer Institute (NCI), invites applications for research projects that investigate the effects of Erythropoietin (EPO) on tumor cell growth. EPO has been widely used to relieve the anemia associated with renal failure. In addition, EPO and other erythropoiesis stimulating agents (ESAs) have recently been used to treat the anemia associated with cancer chemotherapy. However, several clinical trials involving administration of ESAs, have suggested that ESAs may accelerate tumor progression and increase mortality in cancer patients. It is therefore important to understand the biology of ESAs on tumor cell growth and apoptosis. The purpose of this FOA is to stimulate high quality research on the effects of ESAs on tumor cell biology and tumor progression.

This FOA uses the NIH research project R01 grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-09-024 that encourages applications under the NIH Exploratory/Developmental (R21) Grant mechanism. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total project period for an application submitted in response to this funding opportunity may not exceed 5 years. Applicants for an R01 award are not limited in dollars but need to reflect the actual needs of the proposed project. The R01 application Research Plan component of the PHS398 (Items 2–5) may not exceed 25 pages, including tables, graphs, figures, diagrams, and charts (see also http://grants.nih.gov/grants/funding/funding_program.htm).

Eligible institutions and organizations include: public and state controlled institutions of higher education; private institutions of higher education; Hispanic-serving institutions; nonprofit organizations with 501(c)(3) IRS status (other than institutions of higher education); nonprofit organizations without 501(c)(3) IRS status (other than institutions of higher education); small businesses; for-profit organizations (other than small businesses); state governments; county governments; city or township governments; special district governments; Independent School Districts; U.S. territories or possessions; regional organizations; non-domestic (non-U.S.) entities (foreign organizations); eligible agencies of the federal government; and faith-based or community-based organizations. Individuals with the

skills, knowledge, and resources necessary to carry out the proposed research are invited to work with their institution/ organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. More than one PD/PI (i.e., multiple PDs/PIs) may be designated on the application. Applicants may submit more than one appli-

cation, provided each application is scientifically distinct. Applicants may submit a resubmission application, but such application must include an Introduction addressing the previous peer review critique (Summary Statement). Applicants may submit a renewal application.

Complete details available online at <http://grants.nih.gov/grants/guide/pa-files/PA-09-023.html>